Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid- dependent asthma

Sanjiv Sur, M. Camara, A. Buchmeier, S. Morgan, H. S. Nelson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pyridoxine has been reported to largely correct an abnormality of tryptophan metabolism present in patients with bronchial asthma and to reduce the symptoms of asthma in long-term studies. We enrolled 31 patients requiring steroids (oral or inhaled) for the treatment of their asthma in a double-blind, placebo-controlled assessment of 9 weeks' treatment with pyridoxine 300 mg per day (13) or placebo (18). Outcome variables included PEFR, FEV1, asthma symptom scores, 24 hour urinary 5-HIAA, skin test reactivity to histamine and compound 48/80 and blood serotonin levels. Plasma pyridoxine levels indicated overall patient compliance with a mean change from baseline to the end of the study of 82.5 ± 27.7 ng/mL in patients on pyridoxine and -2.9 ± 10.3 for those on placebo (P = .0001). Furthermore, patients routinely treated with theophylline had lower (10 ± 8 ng/mL) plasma pyridoxine levels at baseline than those not on it (19 ± 6 ng/mL; P = .01), suggesting that theophylline may lower plasma pyridoxine levels. There was no significant difference between the pyridoxine and placebo groups in the change from baseline to the last 2 weeks of the treatment phase in any of the outcome variables. We conclude that under the conditions of the study, treatment with oral pyridoxine failed to improve the outcome variables in patients requiring steroids for the treatment of their asthma. The results of this study suggest that prescription or usage of oral pyridoxine for the treatment of asthma cannot be justified in such patients.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalAnnals of Allergy
Volume70
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

Pyridoxine
Vitamin B 6
Asthma
Steroids
Placebos
Therapeutics
Theophylline
p-Methoxy-N-methylphenethylamine
Peak Expiratory Flow Rate
Hydroxyindoleacetic Acid
Patient Compliance
Skin Tests
Tryptophan
Histamine
Prescriptions
Serotonin

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Sur, S., Camara, M., Buchmeier, A., Morgan, S., & Nelson, H. S. (1993). Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid- dependent asthma. Annals of Allergy, 70(2), 147-152.

Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid- dependent asthma. / Sur, Sanjiv; Camara, M.; Buchmeier, A.; Morgan, S.; Nelson, H. S.

In: Annals of Allergy, Vol. 70, No. 2, 1993, p. 147-152.

Research output: Contribution to journalArticle

Sur, S, Camara, M, Buchmeier, A, Morgan, S & Nelson, HS 1993, 'Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid- dependent asthma', Annals of Allergy, vol. 70, no. 2, pp. 147-152.
Sur S, Camara M, Buchmeier A, Morgan S, Nelson HS. Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid- dependent asthma. Annals of Allergy. 1993;70(2):147-152.
Sur, Sanjiv ; Camara, M. ; Buchmeier, A. ; Morgan, S. ; Nelson, H. S. / Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid- dependent asthma. In: Annals of Allergy. 1993 ; Vol. 70, No. 2. pp. 147-152.
@article{14e8ad3b8fb0410aa90313f8ac7b46b6,
title = "Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid- dependent asthma",
abstract = "Pyridoxine has been reported to largely correct an abnormality of tryptophan metabolism present in patients with bronchial asthma and to reduce the symptoms of asthma in long-term studies. We enrolled 31 patients requiring steroids (oral or inhaled) for the treatment of their asthma in a double-blind, placebo-controlled assessment of 9 weeks' treatment with pyridoxine 300 mg per day (13) or placebo (18). Outcome variables included PEFR, FEV1, asthma symptom scores, 24 hour urinary 5-HIAA, skin test reactivity to histamine and compound 48/80 and blood serotonin levels. Plasma pyridoxine levels indicated overall patient compliance with a mean change from baseline to the end of the study of 82.5 ± 27.7 ng/mL in patients on pyridoxine and -2.9 ± 10.3 for those on placebo (P = .0001). Furthermore, patients routinely treated with theophylline had lower (10 ± 8 ng/mL) plasma pyridoxine levels at baseline than those not on it (19 ± 6 ng/mL; P = .01), suggesting that theophylline may lower plasma pyridoxine levels. There was no significant difference between the pyridoxine and placebo groups in the change from baseline to the last 2 weeks of the treatment phase in any of the outcome variables. We conclude that under the conditions of the study, treatment with oral pyridoxine failed to improve the outcome variables in patients requiring steroids for the treatment of their asthma. The results of this study suggest that prescription or usage of oral pyridoxine for the treatment of asthma cannot be justified in such patients.",
author = "Sanjiv Sur and M. Camara and A. Buchmeier and S. Morgan and Nelson, {H. S.}",
year = "1993",
language = "English (US)",
volume = "70",
pages = "147--152",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "2",

}

TY - JOUR

T1 - Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid- dependent asthma

AU - Sur, Sanjiv

AU - Camara, M.

AU - Buchmeier, A.

AU - Morgan, S.

AU - Nelson, H. S.

PY - 1993

Y1 - 1993

N2 - Pyridoxine has been reported to largely correct an abnormality of tryptophan metabolism present in patients with bronchial asthma and to reduce the symptoms of asthma in long-term studies. We enrolled 31 patients requiring steroids (oral or inhaled) for the treatment of their asthma in a double-blind, placebo-controlled assessment of 9 weeks' treatment with pyridoxine 300 mg per day (13) or placebo (18). Outcome variables included PEFR, FEV1, asthma symptom scores, 24 hour urinary 5-HIAA, skin test reactivity to histamine and compound 48/80 and blood serotonin levels. Plasma pyridoxine levels indicated overall patient compliance with a mean change from baseline to the end of the study of 82.5 ± 27.7 ng/mL in patients on pyridoxine and -2.9 ± 10.3 for those on placebo (P = .0001). Furthermore, patients routinely treated with theophylline had lower (10 ± 8 ng/mL) plasma pyridoxine levels at baseline than those not on it (19 ± 6 ng/mL; P = .01), suggesting that theophylline may lower plasma pyridoxine levels. There was no significant difference between the pyridoxine and placebo groups in the change from baseline to the last 2 weeks of the treatment phase in any of the outcome variables. We conclude that under the conditions of the study, treatment with oral pyridoxine failed to improve the outcome variables in patients requiring steroids for the treatment of their asthma. The results of this study suggest that prescription or usage of oral pyridoxine for the treatment of asthma cannot be justified in such patients.

AB - Pyridoxine has been reported to largely correct an abnormality of tryptophan metabolism present in patients with bronchial asthma and to reduce the symptoms of asthma in long-term studies. We enrolled 31 patients requiring steroids (oral or inhaled) for the treatment of their asthma in a double-blind, placebo-controlled assessment of 9 weeks' treatment with pyridoxine 300 mg per day (13) or placebo (18). Outcome variables included PEFR, FEV1, asthma symptom scores, 24 hour urinary 5-HIAA, skin test reactivity to histamine and compound 48/80 and blood serotonin levels. Plasma pyridoxine levels indicated overall patient compliance with a mean change from baseline to the end of the study of 82.5 ± 27.7 ng/mL in patients on pyridoxine and -2.9 ± 10.3 for those on placebo (P = .0001). Furthermore, patients routinely treated with theophylline had lower (10 ± 8 ng/mL) plasma pyridoxine levels at baseline than those not on it (19 ± 6 ng/mL; P = .01), suggesting that theophylline may lower plasma pyridoxine levels. There was no significant difference between the pyridoxine and placebo groups in the change from baseline to the last 2 weeks of the treatment phase in any of the outcome variables. We conclude that under the conditions of the study, treatment with oral pyridoxine failed to improve the outcome variables in patients requiring steroids for the treatment of their asthma. The results of this study suggest that prescription or usage of oral pyridoxine for the treatment of asthma cannot be justified in such patients.

UR - http://www.scopus.com/inward/record.url?scp=0027499762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027499762&partnerID=8YFLogxK

M3 - Article

C2 - 8430923

AN - SCOPUS:0027499762

VL - 70

SP - 147

EP - 152

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 2

ER -